Wolfe Research Starts Teva Pharma (TEVA) at Peerperform

Wolfe Research analyst Akash Tewari initiates coverage on Teva Pharma (NYSE: TEVA) with a Peerperform rating and a price target of $9.00.

The analyst comments "TEVA’s stock has lost ~47% YTD which marks material underperformance when compared to the DRG and S&P-500, which have gained ~2% and ~20%, respectively, over the same time period."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $7.83 yesterday.

You May Also Be Interested In

• B.Riley Starts Weave Communications Inc (WEAV) at Buy
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'
• TD Cowen Reiterates Buy Rating on Broadcom Limited (AVGO), neutral into the print